Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR. 18.

被引：0
|
作者：
Leighl, NB
Shepherd, F
Paz-Ares, L
Douillard, JY
Peschel, C
Arnold, A
Tu, D
Galbraith, S
Hann, K
Seymour, L
机构：
[1] Natl Canc Inst Canada, Kingston, ON, Canada
[2] Bristol Myers Squibb, Wallingford, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7038
引用
收藏
页码：626S / 626S
页数：1
相关论文
共 50 条
  • [1] Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer
    Douillard, JY
    Peschel, C
    Shepherd, F
    Paz-Ares, L
    Arnold, A
    Davis, M
    Tonato, M
    Smylie, M
    Tu, DS
    Voi, M
    Humphrey, J
    Ottaway, J
    Young, K
    Van Vreckem, A
    Seymour, L
    LUNG CANCER, 2004, 46 (03) : 361 - 368
  • [2] Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
    Leighl, NB
    Paz-Ares, L
    Douillard, JY
    Peschel, C
    Arnold, A
    Depierre, A
    Santoro, A
    Betticher, DC
    Gatzemeier, U
    Jassem, J
    Crawford, J
    Tu, DS
    Bezjak, A
    Humphrey, JS
    Voi, M
    Galbraith, S
    Hann, K
    Seymour, L
    Shepherd, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2831 - 2839
  • [3] Pharmacokinetic interaction study evaluating the effect of BMS-275291 on the pharmacokinetics of paclitaxel and carboplatin in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Malik, SM
    Hwang, JJ
    Belani, CP
    Galbraith, S
    Bai, S
    Rizvi, NA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 693S - 693S
  • [4] Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Blumenschein, G. R.
    Kabbinavar, F. F.
    Menon, H.
    Mok, T.
    Stephenson, J.
    Beck, J. T.
    Lakshmaiah, K.
    Kracht, K.
    Sikorski, R. S.
    Schwartzberg, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Phase I/II study of atrasentan (A) in combination with carboplatin (C) and paclitaxel (P) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Chiappori, A
    Haura, E
    Williams, C
    Simon, G
    Antonia, S
    Cantor, A
    Burton, MK
    Lush, R
    Sullivan, DM
    Bepler, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 646S - 646S
  • [6] Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung Cancer
    Jahnke, Kristoph
    Keilholz, Ulrich
    Lueftner, Diana
    Thiel, Eckhard
    Schmittel, Alexander
    ANTICANCER RESEARCH, 2011, 31 (01) : 317 - 323
  • [7] Phase II study of Docetaxel (D) and Carboplatin (C) combination in advanced Non-Small Cell Lung Cancer (NSCLC)
    Chowdhury, Qamruzzaman
    Begum, Ferdous A.
    Nahar, Ferdous
    Fairuz, Saima
    Faruqui, Mesba
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S673 - S673
  • [8] Meloxicam (M) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced non-small cell lung cancer (NSCLC).
    Takahashi, T
    Kogure, Y
    Ueda, S
    Ebisawa, M
    Asai, G
    Yamamoto, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
  • [9] A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small lung cancer (NSCLC)
    Blackhall, F. H.
    Mark, Z.
    Zatloukal, P.
    Szima, B.
    Albert, I.
    Juhasz, E.
    Yang, X.
    Smethurst, D.
    Hei, Y.
    Soria, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC)
    Fidias, P.
    Ciuleanu, T. A.
    Gladkov, O.
    Manikhas, G. M.
    Bondarenko, I. N.
    Pluzanska, A.
    Ramlau, R.
    Lynch, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
12345